Nimorazole

09/01/2016 - "In head and neck squamous cell carcinomas (HNSCC) hypoxic radioresistance can be reduced by use of the hypoxic modifier nimorazole, as shown in the DAHANCA 5 trial. "
03/01/2015 - "To study the pharmacokinetic characteristics of the hypoxic radiosensitiser nimorazole in patients with head and neck squamous cell carcinoma. "
06/01/2007 - "The aim of the present study was to investigate whether CA IX served as a prognostic factor for outcome in a large population of HNSCC and if CA IX was able to discriminate the tumours that did benefit from hypoxic modification with nimorazole. "
01/01/2021 - "This cohort was treated with accelerated fractionated chemo-IMRT, with/without the hypoxic radiosensitizer Nimorazole for HNSCC. "
05/01/2014 - "Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC)."

09/01/2013 - "The aim of the present study was to determine radiosensitivity, the impact of hypoxia and the effect of Nimorazole in HPV positive and HPV negative cell lines. "
01/01/2023 - "Our results suggest that nimorazole combined with RCTx might improve TCR compared to RCTx alone if hypoxia is decreased during the course of RCTx but further experiments are warranted to verify this association. "
02/01/2015 - "(18)F-FAZA PET may be useful to guide hypoxia-directed RT using nimorazole as radiosensitizer. "
09/01/2013 - "The clinical observation that HPV positive patients do not seem to benefit from Nimorazole treatment is not due to inherent differences in hypoxia sensitivity or response to Nimorazole, but can be accounted for by the overall higher radiosensitivity of HPV positive cells."
09/01/2013 - "Although HPV positive cells had a markedly higher radiosensitivity compared to HPV negative cells, they displayed the same relative radioresistance under hypoxia and the same relative sensitizer effect of Nimorazole. "

01/01/2023 - "Nimorazole combined with RCTx significantly improved permanent local control in two tumor models, and showed a potential improvement in two additional models. "
03/07/2018 - "In vitro, pre-treatment with nimorazole significantly decreased hypoxic radioresistance (P < 0.01) while in vivo, nimorazole enhanced the efficacy of RT to suppress cancer cell proliferation in hypoxic tumor areas (Ki67, P = 0.064), but did not affect macroscopic tumor growth. "
11/01/2023 - "Analyses adjusting for nimorazole, tumor stage, baseline BMI, mean radiation dose to constrictor muscles and oral cavity confirmed this. "
09/20/2003 - "All patients, except those with glottic cancers, also received the hypoxic radiosensitiser nimorazole. "
02/01/1998 - "Nimorazole significantly improves the effect of radiotherapeutic management of supraglottic and pharynx tumors and can be given without major side-effects."

03/01/2015 - "Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial."
01/01/2003 - "Treatment of head and neck cancer with CHART and nimorazole: phase II study."
05/01/2014 - "To evaluate the compliance and toxicity of the hypoxic radiosensitizer nimorazole in head and neck cancer patients. "
01/01/2003 - "Nimorazole is the only such agent to have shown a significant effect in a randomized controlled trial in head and neck cancer. "
11/01/1998 - "Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer."

12/01/1973 - "[Study of Nimorazole in Trichomonas genital infections]."
02/01/1979 - "Both forms of infection with IR-78 could always be cured with therapeutically acceptable doses of tinidazole and nimorazole; subcutaneous infections could not be cured with tolerated doses of metronidazole."
06/01/1983 - "CG 10213-Go, a 5-nitroimidazole derivative synthesized at the CIBA-Geigy Research Centre, Bombay, proved superior to such currently used 5-nitroimidazole derivatives as metronidazole, ornidazole, secnidazole, tinidazole and nimorazole, against experimental amoebic infections of the liver and caecum in a golden hamster model. "